In conjunction with the Society for Immunotherapy of Cancer (SITC), Discern Health Partner Tom Valuck and Director David Blaisdell co-authored the new Journal of ImmunoTherapy of Cancer (JITC) article, “Defining Current Gaps in Quality Measures for Cancer Immunotherapy: Consensus Report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit.”
The article identifies four National Quality Strategy domains with significant gaps. These findings are based on a SITC-convened, multi-stakeholder expert panel facilitated by Discern, which was created to identify current gaps in measures of quality cancer care delivery related to immunotherapy and to advance priority concepts surrounding quality measures that could be developed and broadly adopted by the field. This work is a first step toward defining and standardizing quality delivery of cancer immunotherapy.
Read the article here.